Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000540910
Ethics application status
Approved
Date submitted
2/04/2020
Date registered
4/05/2020
Date last updated
4/05/2020
Date data sharing statement initially provided
4/05/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer
Scientific title
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer
Secondary ID [1] 299465 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Oral Mucositis 314681 0
Head and Neck Cancer 316585 0
Condition category
Condition code
Cancer 313028 313028 0 0
Head and neck
Oral and Gastrointestinal 313029 313029 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This Phase 2 part of the study will be a double-blind, randomised, placebo-controlled study to:

• Evaluate and compare the efficacy of a daily dose of ST-617 on reducing the duration and severity of severe oral mucositis (OM) in patients receiving concomitant chemoradiation for the treatment of cancers of the oral cavity, oropharynx, hypopharynx, and nasopharynx.

• Assess the acute and long-term safety of ST-617.

Participants will receive an oral suspension, either ST-617 or a placebo treatment equivalent to the volume of the study drug. The placebo will look and taste very similar to the study drug and will be supplied in identical bottles/caps. ST-Placebo has an added sub-pharmacologic level of quinine as the bitter flavouring to mimic the active ingredient in ST-617.

ST-617 at its recommended Phase 2 dose (RP2D), which will be determined from the Phase 1b study, will be administered daily for 3 days prior to the start of radiation, and then daily during radiation treatment. On days of radiation treatment, ST-617 or placebo will be administered and completely consumed 60 minutes to 120 minutes prior to each day’s radiation treatment. On days that patients will not have radiation treatment, ST-617 will be administered at the same time of day as it had been on days of radiation. Every patient, regardless of placebo or study drug administration, will receive best supportive care (BSC) for the prevention of oral mucositis.

BSC is defined as a specific oral hygiene regimen based on current guidelines, and practices to minimise the risk of mucosal injury and reduce the risk of secondary oral infection. To assure compliance each patient will be provided with a kit containing supplies necessary for BSC and instructions regarding its use. During the study, patients will be given a kit that has been specifically designed for patients at risk of radiation induced dental disease. This kit contains a toothbrush, toothpaste, dental floss, fluoride gel, oral rinse, and chewing gum. Patients will also receive instructions on how best to use these items to lower the amounts of bacteria on teeth and gums and make teeth more resistant to tooth decay.
Radiation treatment duration will last for up to approximately 6 to 8 weeks, however this duration will vary among participants and will depend on clinician's discretion.

Accountability for the study drug at the study site is the responsibility of the Investigator. The Investigator will ensure that the study drug is used only in accordance with the study protocol. The Investigator may assign the drug accountability responsibilities to a pharmacist or other appropriately trained individual; however, the Investigator remains ultimately responsible for drug accountability.

Drug accountability records indicating the drug’s delivery date to the site, inventory at the site and use/dispensing will be maintained. These records will adequately document that study drugs were used and dispensed as specified in the study protocol.
Accountability records will include dates, quantities, batch/lot numbers, number of vials, and patient numbers. The Sponsor (or its designee) will review drug accountability records at the site on an ongoing basis during the study. All unused supplies must be inventoried, accounted for, and returned to Sponsor (or its designee), or if authorised, disposed of at the study site. Records of disposal must be maintained with the study records.
To ensure compliance each patient will be provided with a kit containing supplies necessary for BSC and instructions regarding their use.
Intervention code [1] 315715 0
Treatment: Drugs
Comparator / control treatment
ST-617, an oral suspension, will be compared to a placebo treatment, also an oral suspension, in equivalent volume to the active drug. The placebo will look and taste very similar to the active ingredient and is supplied in identical bottles/caps. ST-Placebo has an added sub-pharmacologic level of quinine as the bitter flavoring to mimic the active ingredient. The placebo dosage should be prepared exactly as that described for the active drug.
Control group
Placebo

Outcomes
Primary outcome [1] 321580 0
Duration of, equal to or greater than, Grade 3 oral mucositis as determined by the World Health Organisation (WHO) oral mucositis assessment scale.

Incidence of oral mucositis will be assessed by trained assessors using a structured template developed by Primary Endpoint Solutions (PES). Data collection will be standardised, and oral mucositis scores will be centrally assigned by PES to the WHO, National Cancer Institute (NCI)and Radiation Therapy Oncology Group (RTOG) scales based on the information provided.
Timepoint [1] 321580 0
OM assessments will be done at Screening, before each weekly treatment on Day 1, and then twice weekly with at least 48 hours between assessments, and then once weekly (if necessary) after cessation of radiation therapy until OM resolves to less than or equal to Grade 1 or until start of new treatment. OM will also be assessed at the End of Treatment Visit and the 30-Day Safety Follow-Up Visit.

The End of Treatment visit will be assessed on the last day of the last week that participants receive radiation therapy. Participants will be asked to come to the clinic for approximately 1-2 hours to complete the required tests (e.g. heart rate, blood pressure, breathing rate and body temperature) and answer straight forward questions (e.g. whether any adverse events were experienced).
Secondary outcome [1] 375446 0
Incidence of severe oral mucositis.

Incidence of OM will be assessed by trained assessors using a structured template developed by PES. Data collection will be standardised, and oral mucositis scores will be centrally assigned by PES to the WHO, NCI and RTOG scales based on the information provided.
Timepoint [1] 375446 0
Oral mucositis assessments will be done at Screening, before each weekly treatment on Day 1, and then twice weekly with at least 48 hours between assessments, and then once weekly (if necessary) after cessation of radiation therapy until oral mucositis resolves to less than or equal to Grade 1 or until start of new treatment. Oral mucositis will also be assessed at the End of Treatment Visit and the 30-Day Safety Follow-Up Visit.

The End of Treatment visit will be assessed on the last day of the last week that participants receive radiation therapy. Participants will be asked to come to the clinic for approximately 1-2 hours to complete the required tests (e.g. heart rate, blood pressure, breathing rate and body temperature) and answer straight forward questions (e.g. whether any adverse events were experienced).
Secondary outcome [2] 375447 0
Incidence of ulcerative mucositis.

The incidence of ulcerative mucositis will be assessed by clinicians that employ assessment scales developed by the World Health Organisation, National Cancer Institute and Radiation Therapy Oncology Group.
Timepoint [2] 375447 0
OM assessments will be done at Screening, before each weekly treatment on Day 1, and then twice weekly with at least 48 hours between assessments, and then once weekly (if necessary) after cessation of radiation therapy until oral mucositis resolves to less than or equal to Grade 1 or until start of new treatment. OM will also be assessed at the End of Treatment Visit and the 30-Day Safety Follow-Up Visit.

The End of Treatment visit will be assessed on the last day of the last week that participants receive radiation therapy. Participants will be asked to come to the clinic for approximately 1-2 hours to complete the required tests (e.g. heart rate, blood pressure, breathing rate and body temperature) and answer straight forward questions (e.g. whether any adverse events were experienced).
Secondary outcome [3] 375448 0
Time in onset of greater than, or equal to, Grade 3 oral mucositis as determined by WHO oral mucositis assessment scale.

Time to onset of greater than, or equal to, Grade 3 oral mucositis will be assessed by clinicians that employ assessment scales developed by the WHO, NCI and RTOG.
Timepoint [3] 375448 0
OM assessments will be done at Screening, before each weekly treatment on Day 1, and then twice weekly with at least 48 hours between assessments, and then once weekly (if necessary) after cessation of radiation therapy until OM resolves to less than or equal to Grade 1 or until start of new treatment. OM will also be assessed at the End of Treatment Visit and the 30-Day Safety Follow-Up Visit.

The End of Treatment visit will be assessed on the last day of the last week that participants receive radiation therapy. Participants will be asked to come to the clinic for approximately 1-2 hours to complete the required tests (e.g. heart rate, blood pressure, breathing rate and body temperature) and answer straight forward questions (e.g. whether any adverse events were experienced).
Secondary outcome [4] 375449 0
Time to onset of ulcerative mucositis.

Time to onset of ulcerative mucositis will be assessed by clinicians that employ assessment scales developed by the WHO, NCI and RTOG.
Timepoint [4] 375449 0
OM assessments will be done at Screening, before each weekly treatment on Day 1, and then twice weekly with at least 48 hours between assessments, and then once weekly (if necessary) after cessation of radiation therapy until OM resolves to less than or equal to Grade 1 or until start of new treatment. OM will also be assessed at the End of Treatment Visit and the 30-Day Safety Follow-Up Visit.

The End of Treatment visit will be assessed on the last day of the last week that participants receive radiation therapy. Participants will be asked to come to the clinic for approximately 1-2 hours to complete the required tests (e.g. heart rate, blood pressure, breathing rate and body temperature) and answer straight forward questions (e.g. whether any adverse events were experienced).
Secondary outcome [5] 375450 0
Time to onset of opioid use due to mouth pain.

Time to onset of opioid use due to mouth pain will be assessed as per normal protocols and standard care regimens using patient medical records, regardless of patients having entered this study as patients can unfortunately be exposed to pain during chemotherapy and as such our aim is to minimise this pain and provide them with adequate treatment.
Timepoint [5] 375450 0
OM assessments will be done at Screening, before each weekly treatment on Day 1, and then twice weekly with at least 48 hours between assessments, and then once weekly (if necessary) after cessation of radiation therapy until oral mucositis resolves to less than or equal to Grade 1 or until start of new treatment. OM will also be assessed at the End of Treatment Visit and the 30-Day Safety Follow-Up Visit.

The End of Treatment visit will be assessed on the last day of the last week that participants receive radiation therapy. Participants will be asked to come to the clinic for approximately 1-2 hours to complete the required tests (e.g. heart rate, blood pressure, breathing rate and body temperature) and answer straight forward questions (e.g. whether any adverse events were experienced).
Secondary outcome [6] 375451 0
Change in patient-reported mouth pain.

The Oral Mucositis Daily Questionnaire (OMQD) , developed by PES, will be used to assess patient-reported mouth pain.
Timepoint [6] 375451 0
Participants will be asked to complete the OMQD at the start of the first dose of the study drug (3 days prior to the initiation of radiation), and then daily through to the 30-Day Safety Follow-Up Visit.

This questionnaire will be used by participants to assess a change in patient-reported mouth pain.
Secondary outcome [7] 381030 0
Change in analgesic use.

The OMQD, developed by PES, will be used to assess a change in analgesic use.
Timepoint [7] 381030 0
Participants will be asked to complete the OMQD at the start of the first dose of the study drug (3 days prior to the initiation of radiation), and then daily through to the 30-Day Safety Follow-Up Visit.

This questionnaire will be used by participants to assess a change in analgesic use.
Secondary outcome [8] 381031 0
Duration of ulcerative mucositis.

The duration of ulcerative mucositis will also be assessed by clinicians that employ assessment scales developed by the WHO, NCI and RTOG.
Timepoint [8] 381031 0
OM assessments will be done at Screening, before each weekly treatment on Day 1, and then twice weekly with at least 48 hours between assessments, and then once weekly (if necessary) after cessation of radiation therapy until OM resolves to less than or equal to Grade 1 or until start of new treatment. Oral mucositis will also be assessed at the End of Treatment Visit and the 30-Day Safety Follow-Up Visit.

The End of Treatment visit will be assessed on the last day of the last week that participants receive radiation therapy. Participants will be asked to come to the clinic for approximately 1-2 hours to complete the required tests (e.g. heart rate, blood pressure, breathing rate and body temperature) and answer straight forward questions (e.g. whether any adverse events were experienced).

Eligibility
Key inclusion criteria
Patient Inclusion Criteria
Each patient must meet all the following criteria to participate in the study:

1. Histopathologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or nasopharynx.

2. Unknown Human Papillomavirus (HPV) positive primaries thought to be of oropharyngeal origin may be included if other inclusion criteria are met.

3. Documentation of HPV status for tumors of the oropharynx, tonsils or base of tongue. HPV status is determined by testing of the tumor (not an oral swab).

4. Planned therapy to include a continuous course of external beam radiation to include intensity-modulated radiotherapy (IMRT) with concurrent cisplatin monotherapy administered every week (30-40 mg/m2 for 6-7 doses) or every 3-weeks (60-100 mg/m2 for 3 doses).

5. Planned total radiation dose of between 60-72 Gy administered in single daily fractions of 2.0-2.2 Gy.

6. Radiation field must include at least 2 mucosal sites within the oral cavity (buccal mucosa, floor of mouth, lateral or ventral tongue, anterior tonsillar pillars, or soft palate) in which both sites receive a minimum cumulative radiation dose of 55 Gy.

7. Patient able to voluntarily provide written informed consent to participate in the study.

8. Capable of understanding and complying with the protocol requirements.

9. Adult patients aged between 18 to 75 years old.

10. Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 2.

11. Adequate organ and bone marrow function as defined by:
a. Absolute neutrophil count (ANC) greater than or equal to 1.0 × 10^9/L (1,000/mm^3).
b. Haemoglobin (Hgb) greater than or equal to 9.0 g/dL.
c. Platelets greater than or equal to 75 × 10^9/L (75,000/mm^3).
d. Bilirubin less than or equal to 1.5 x the upper limit of normal (ULN).
e. Serum creatinine less than or equal to 1.5 x ULN or calculated creatinine clearance greater than or equal to 60 mL/min.
f. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULN if no liver involvement, or less than or equal to 5 x ULN with liver involvement.
g. Albumin less than or equal to 3.5 g/dL or within normal range.

12. No evidence of any active oral mucositis (must be Grade 0 on WHO scale).

13. Ability to swish and swallow fluids in mouth without difficulty.

14. Able to minimise time in direct sunlight while on protocol.

15. Sexually active patients must agree to use medically-accepted barrier methods of contraception (e.g., male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 3 months after the last dose of study drug.

16. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test at screening. WCBP includes any woman who has experienced menarche and who has not undergone successful surgical sterilisation (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal.

17. Patient’s written informed consent to test for the human immunodeficiency virus (HIV).
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Patient Exclusion Criteria
Patients who meet any of the following criteria will be excluded from the study:

1. Planned continuation of cisplatin or other chemotherapy following radiotherapy.

2. Patients with known infection of Human Immunodeficiency Virus (HIV) or have clinical signs and symptoms consistent with current HIV infection.

3. Known presence in serum of Hepatitis B surface antigen.

4. Evidence of any current active oral mucositis (must be Grade 0 on WHO scale).

5. Prior treatment including:
a. Radiotherapy or brachytherapy to the head and neck;
b. Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within 3 weeks, or nitrosoureas / mitomycin C within 6 weeks before the first dose of study treatment;
c. Treatment with therapeutic antibody less than 4 weeks before the first dose of study treatment;
d. Small molecule kinase inhibitor or other small molecule investigational agent within 14 days or 5 half-lives of the compound or active metabolites, whichever is greater, before the first dose of study treatment.

6. The patient has not recovered from toxicity due to all prior therapies (i.e., return to pre-therapy baseline or to Grade 0). Persistent > Grade 0 toxicity from prior therapy will be considered by the Sponsor for inclusion if there is no evidence of an overlapping ST-617 toxicity.

7. Major surgery within 21 days prior to first dose of study drug.

8. Current untreated or unresolved oral candidiasis or oral herpes simplex virus (HSV) infection.

9. History of thromboembolic or peripheral vascular disease (including Raynaud’s and systemic lupus erythematosus (SLE)).

10. Grade 2 or greater baseline neuropathy.

11. History of malabsorption or other gastrointestinal disease that may significantly alter the absorption of ST-617 (e.g., greater than or equal to Grade 2 nausea, vomiting or diarrhea).

12. History of poorly controlled Type 1 or Type 2 diabetes mellitus, with a haemoglobin A1c greater than or equal to 8%.

13. Uncontrolled significant intercurrent illness including, but not limited to, ongoing or active infection, history of congestive heart failure within 6 months, hypertension, unstable angina pectoris within 6 months, stroke within 6 months, myocardial infarction within 6 months, or cardiac arrhythmias. (Controlled chronic atrial fibrillation will not be excluded).

14. QTc interval corrected by Fridericia’s method greater than 450 msec for male patients or greater than 470 msec for female patients or history or risk factors for or use of medications known to prolong QTc interval or that may be associated with Torsades de Pointes (TdP) within 7 days of treatment start. CredibleMeds list of drugs known to cause TdP may be used as a reference for this study to determine which drugs are prohibited using the following link: https://crediblemeds.org/new-drug-list or a crediblemeds mobile application.

15. History of other medical or psychiatric illness or organ dysfunction which, in the opinion of the Investigator, would either compromise the patient’s safety or interfere with the evaluation of the safety of the study agent.

16. Concurrent administration of strong inhibitors of CYP3A4.

17. Concurrent administration of drugs that enhance photosensitivity.

18. The patient has a previously identified allergy or hypersensitivity to components of the study treatment formulation, dithiolethiones or platinum compounds.

19. Pregnant or breast-feeding women.

20. Unable to eat a solid diet due to sequelae of surgery or tumor, or gastrostomy-feeding dependence at baseline.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/05/2021
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
110
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC

Funding & Sponsors
Funding source category [1] 303965 0
Commercial sector/Industry
Name [1] 303965 0
Supportive Therapeutics LLC
Country [1] 303965 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
PSI CRO Australia Pty. Ltd.
Address
Suite 2.01, 16 Giffnock Avenue, Macquarie Park, NSW 2113
Country
Australia
Secondary sponsor category [1] 304135 0
Commercial sector/Industry
Name [1] 304135 0
Supportive Therapeutics LLC
Address [1] 304135 0
One Broadway, 14th Floor, Cambridge, MA 02142
Country [1] 304135 0
United States of America

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 304466 0
Central Adelaide Local Health Network Human Research Ethics Committee
Ethics committee address [1] 304466 0
Ethics committee country [1] 304466 0
Australia
Date submitted for ethics approval [1] 304466 0
Approval date [1] 304466 0
10/04/2019
Ethics approval number [1] 304466 0
Ethics committee name [2] 305708 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [2] 305708 0
Ethics committee country [2] 305708 0
Australia
Date submitted for ethics approval [2] 305708 0
23/11/2018
Approval date [2] 305708 0
07/05/2019
Ethics approval number [2] 305708 0
HREC/18/SAC/413

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 97042 0
Dr Hien Le
Address 97042 0
Department of Radiation Oncology, Royal Adelaide Hospital, Port Road, Adelaide, South Australia, 5000
Country 97042 0
Australia
Phone 97042 0
+61 8 8222 4391
Fax 97042 0
Email 97042 0
[email protected]
Contact person for public queries
Name 97043 0
Justine Lee
Address 97043 0
PSI CRO Australia Pty. Ltd.
Suite 2.01, 16 Giffnock Avenue, Macquarie Park, New South Wales, 2113.
Country 97043 0
Australia
Phone 97043 0
+61 2 8582 1672
Fax 97043 0
Email 97043 0
[email protected]
Contact person for scientific queries
Name 97044 0
Justine Lee
Address 97044 0
PSI CRO Australia Pty. Ltd.
Suite 2.01, 16 Giffnock Avenue, Macquarie Park, New South Wales, 2113.
Country 97044 0
Australia
Phone 97044 0
+61 2 8582 1672
Fax 97044 0
Email 97044 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
IPD will not be shared due to patient confidentiality and privacy.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.